Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Imunon, Inc. (IMNN) has a very important June 2025 planned with multiple presentations at prestigious scientific conferences and the publication of the full data set from the OVATION 2 trial.</li><li>On June 3, 2025, Dr. Premal Thaker will present updated results from the Phase 1/2 OVATION 2 trial, which includes data showing a median increase in overall survival of 13 months for patients treated with IMNN-001 plus standard of care compared to those just receiving standard of care (HR = 0.69).</li><li>Later in June, Dr. Thaker will be presenting immune biomarker data from the OVATION 2 trial at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025.</li></ul>

Imunon, Inc. (IMNN) has a very important June 2025 planned with multiple presentations at prestigious scientific conferences and the publication of the full data set from the OVATION 2 trial.On June 3, 2025, Dr. Premal Thaker will present updated results from the Phase 1/2 OVATION 2 trial, which includes data showing a median increase in overall survival of 13 months for patients treated with IMNN-001 plus standard of care compared to those just receiving standard of care (HR = 0.69).Later in June, Dr. Thaker will be presenting immune biomarker data from the OVATION 2 trial at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025.

IMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers 